Sign in Subscribe
Pharmaceutical industry

BioMedReports.com Updates Clinical Trials and FDA Calendar Database for Biotech Investors

Strategic Insights

— 1 min read

BioMedReports.com, a news portal covering the biomedical sector, has updated its calendar database of clinical trials and upcoming FDA approvals and decisions for biotech investors. The database now includes detailed information on various biopharmaceutical companies, including Seattle Genetics, Inc. (Nasdaq:SGEN) and Dynavax Technologies Corporation (Nasdaq:DVAX), which recently reported their financial results for the third quarter and nine months ended September 30, 2009. The company's database features a comprehensive list of about 1,000 stocks and exchange-traded funds from the healthcare sector, organized into various new healthcare stock indexes. This comprehensive database is accessible to biotech investors who are interested in staying up-to-date on the latest developments in the biomedical sector.

Key Takeaways:

  • BioMedReports.com has updated its calendar database of clinical trials and upcoming FDA approvals and decisions for biotech investors.
  • The database features detailed information on various biopharmaceutical companies, including Seattle Genetics, Inc. (Nasdaq:SGEN) and Dynavax Technologies Corporation (Nasdaq:DVAX).
  • These companies recently reported their financial results for the third quarter and nine months ended September 30, 2009.
  • BioMedReports.com's database features a comprehensive list of about 1,000 stocks and exchange-traded funds from the healthcare sector, organized into various new healthcare stock indexes.
  • Biotech investors can access this database by visiting BioMedReports.com's website.
  • The database is designed to provide biotech investors with the information they need to make informed investment decisions.

Statistics:

  • About 1,000 stocks and exchange-traded funds from the healthcare sector are featured in BioMedReports.com's database.
  • Seattle Genetics, Inc. (Nasdaq:SGEN) reported a net loss of $751,000 for the third quarter ended September 30, 2009.
  • Dynavax Technologies Corporation (Nasdaq:DVAX) reported a net loss of $19.6 million for the third quarter ended September 30, 2009.

Sources:

  • BioMedReports.com
  • Seattle Genetics, Inc. (Nasdaq:SGEN) financial results for the third quarter ended September 30, 2009
  • Dynavax Technologies Corporation (Nasdaq:DVAX) financial results for the third quarter ended September 30, 2009
  • SmarTrend Alert (Comtex SmarTrend)

Read more